CURRICULUM VITAE

Joanna Lis, MSc, MBA, PhD

Dr. Lis holds a PhD in biostatistics and computer modelling (neural networks, AI) in medicine, MSc in mathematics and physics from the Jagiellonian University in Cracow and an executive MBA from Kozminski University of Business and Management in Warsaw.

Dr. Lis has extensive experience in the use of health economics in Market Access processes, having held management positions at Sanofi and Central & South Europe of Sanofi and previously held various leadership positions in health economics area at Johnson & Johnson and Eli Lilly. These roles allowed her to apply her scientific expertise to real-world healthcare challenges, developing innovative approaches to demonstrate the value of medical innovations. Currently, as Market Access Excellence Lead for Central & South Europe at Sanofi, Dr. Lis leverages her comprehensive understanding of healthcare systems to ensure patient access to innovative treatments across multiple countries. Her strategic vision and technical expertise have established her as a respected leader in the field of market access and health economics.

Prior to joining the industry, she was an assistant professor at the Institute of Biocybernetics & Biomedical Engineering of the Polish Academy of Science (PAN) and the Medical Centre of Postgraduate Education for Physicians (CMKP).

She was the President of the ISPOR Polish Chapter (2012-2016) as well as a member of the ISPOR Central and Eastern Europe Network. In 2016-2018 she was the Director in Board of Directors International Society for Pharmacoeconomics & Outcomes Research (ISPOR). As an active member of ISPOR Polish Chapter Management Boars and ISPOR, she has been heavily involved in the ISPOR Patient Registry Special Interest Group: (ISPOR Taxonomy of Patient Registries: Classification, Characteristics and Terms) and ISPOR Task Force for Transferability of Economic Evaluations across Jurisdictions.  Dr. Lis has served as the Co-Chair of the Issue Panel Review Committee at ISPOR 13th Annual European Congress in Prague. Dr. Lis also co-organized the 5th Polish-Russian and Polish- Kazakh-Russian Forums on Pharmacoeconomics. She is also the co-editor of the Polish translation of ISPOR books: “Health Care Cost, Quality and Outcomes: ISPOR Book of Terms” & “Therapeutic & Diagnostic Device Outcomes Research.”

Dr. Lis has contributed as the co-author of the Polish HTA Guidelines adopted by the Polish HTA Agency in Poland and was a member of the experts' team of the Polish HTA Agency working on HTA Guidelines updates and HTA for medical devices Guidelines development for Poland. She was also a leader of one of the pathways in EU Project on FINANCING QUALITY IN HCS: InterQuality; 7th Framework Program.  Dr. Lis was a member of the experts’ team working with HAs on New Reimbursement Law development and implementation in Poland.

She has published over 100 articles in health policy and economics fields. She is a co-author of various books: “Pricing: pharmaceuticals’ prices, negotiations and risk sharing agreements”, “Health Insurance Policy and Benefit Baskets: overview of the solutions” and reports: “Indirect costs in HTA: methods and recommendations”, “Risk Sharing Agreements in Poland”

Until 2017 member of the Editorial Advisory Board of the Journal of Health Policy and Outcomes Research (JHPOR) and from 2017 until present Deputy Editor in Chief of the Journal of Health Policy and Outcomes Research (JHPOR).